PTPRK Expression Is Downregulated in Drug Resistant Ovarian Cancer Cell Lines, and Especially in ALDH1A1 Positive CSCs-Like Populations

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Apr 28

PMID 31027318

Citations 9

Authors

Monika Swierczewska

Karolina Sterzynska

Karolina Wojtowicz

Dominika Kazmierczak

Dariusz Izycki

Michal Nowicki

Maciej Zabel

Radoslaw Januchowski

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer is the 7th most common cancer and 8th most mortal cancer among woman. The standard treatment includes cytoreduction surgery followed by chemotherapy. Unfortunately, in most cases, after treatment, cancer develops drug resistance. Decreased expression and/or activity of protein phosphatases leads to increased signal transduction and development of drug resistance in cancer cells. Using sensitive (W1, A2780) and resistant ovarian cancer cell lines, the expression of Protein Tyrosine Phosphatase Receptor Type K (PTPRK) was performed at the mRNA (real-time PCR analysis) and protein level (Western blot, immunofluorescence analysis). The protein expression in ovarian cancer tissues was determined by immunohistochemistry. The results showed a decreased level of PTPRK expression in ovarian cancer cell lines resistant to cisplatin (CIS), paclitaxel (PAC), doxorubicin (DOX), topotecan (TOP), vincristine (VIN) and methotrexate (MTX). Additionally, the lower PTPRK expression was observed in Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) positive cancer stem cells (CSCs) population, suggesting the role of PTPRK downregulation in primary as well as acquired resistance to cytotoxic drugs. These results provide important insights into the role of PTPRK in mechanism leading to drug resistance in ovarian cancer and has raised important questions about the role of imbalance in processes of phosphorylation and dephosphorylation.

Citing Articles

The Role of Elacridar, a P-gp Inhibitor, in the Re-Sensitization of PAC-Resistant Ovarian Cancer Cell Lines to Cytotoxic Drugs in 2D and 3D Cell Culture Models.

Stasiak P, Sopel J, Lipowicz J, Rawluszko-Wieczorek A, Korbecki J, Januchowski R Int J Mol Sci. 2025; 26(3).

PMID: 39940891 PMC: 11817197. DOI: 10.3390/ijms26031124.

The Promise of Piperine in Cancer Chemoprevention.

Benayad S, Wahnou H, El Kebbaj R, Liagre B, Sol V, Oudghiri M Cancers (Basel). 2023; 15(22).

PMID: 38001748 PMC: 10670142. DOI: 10.3390/cancers15225488.

Bibliometric and visualized analysis of drug resistance in ovarian cancer from 2013 to 2022.

Liu J, Ma J, Zhang J, Li C, Yu B, Choe H Front Oncol. 2023; 13:1173863.

PMID: 37324006 PMC: 10263169. DOI: 10.3389/fonc.2023.1173863.

Clinical effects of TP-based hyperthermic intraperitoneal chemotherapy (HIPEC) on CD133 and HE4 expression in advanced epithelial ovarian cancer.

Su X, Sun X, Wang Y, Kang Y, Dai Y Pak J Med Sci. 2022; 38(6):1508-1513.

PMID: 35991244 PMC: 9378387. DOI: 10.12669/pjms.38.6.5287.

ALDH1A1 in Cancers: Bidirectional Function, Drug Resistance, and Regulatory Mechanism.

Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y Front Oncol. 2022; 12:918778.

PMID: 35814382 PMC: 9256994. DOI: 10.3389/fonc.2022.918778.

References

Davis J, Navolanic P, Saleh O, Steelman L, Franklin R, Robinson P . Role of the Raf signal transduction cascade in the in vitro resistance to the anticancer drug doxorubicin. Clin Cancer Res. 2001; 7(9):2898-907. View

McArdle L, Rafferty M, Maelandsmo G, Bergin O, Farr C, Dervan P . Protein tyrosine phosphatase genes downregulated in melanoma. J Invest Dermatol. 2001; 117(5):1255-60. DOI: 10.1046/j.0022-202x.2001.01534.x. View

Nakamura M, Kishi M, Sakaki T, Hashimoto H, Nakase H, Shimada K . Novel tumor suppressor loci on 6q22-23 in primary central nervous system lymphomas. Cancer Res. 2003; 63(4):737-41. View

Ostman A, Hellberg C, Bohmer F . Protein-tyrosine phosphatases and cancer. Nat Rev Cancer. 2006; 6(4):307-20. DOI: 10.1038/nrc1837. View

Eswaran J, Debreczeni J, Longman E, Barr A, Knapp S . The crystal structure of human receptor protein tyrosine phosphatase kappa phosphatase domain 1. Protein Sci. 2006; 15(6):1500-5. PMC: 2242534. DOI: 10.1110/ps.062128706. View

McCubrey J, Steelman L, Abrams S, Lee J, Chang F, Bertrand F . Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006; 46:249-79. DOI: 10.1016/j.advenzreg.2006.01.004. View

McCubrey J, Steelman L, Chappell W, Abrams S, Wong E, Chang F . Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2006; 1773(8):1263-84. PMC: 2696318. DOI: 10.1016/j.bbamcr.2006.10.001. View

Xie Y, Xu K, Linn D, Yang X, Guo Z, Shimelis H . The 44-kDa Pim-1 kinase phosphorylates BCRP/ABCG2 and thereby promotes its multimerization and drug-resistant activity in human prostate cancer cells. J Biol Chem. 2007; 283(6):3349-3356. DOI: 10.1074/jbc.M707773200. View

Abukhdeir A, Park B . P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008; 10:e19. PMC: 2678956. DOI: 10.1017/S1462399408000744. View

10.

Yap T, Carden C, Kaye S . Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009; 9(3):167-81. DOI: 10.1038/nrc2583. View

11.

Stolarczyk E, Reiling C, Paumi C . Regulation of ABC transporter function via phosphorylation by protein kinases. Curr Pharm Biotechnol. 2010; 12(4):621-35. PMC: 3085954. DOI: 10.2174/138920111795164075. View

12.

Correia A, Bissell M . The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist Updat. 2012; 15(1-2):39-49. PMC: 3658318. DOI: 10.1016/j.drup.2012.01.006. View

13.

Assem M, Sibenaller Z, Agarwal S, Al-Keilani M, Alqudah M, Ryken T . Enhancing diagnosis, prognosis, and therapeutic outcome prediction of gliomas using genomics. OMICS. 2012; 16(3):113-22. PMC: 3300066. DOI: 10.1089/omi.2011.0031. View

14.

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

15.

Januchowski R, Wojtowicz K, Sujka-Kordowska P, Andrzejewska M, Zabel M . MDR gene expression analysis of six drug-resistant ovarian cancer cell lines. Biomed Res Int. 2013; 2013:241763. PMC: 3591129. DOI: 10.1155/2013/241763. View

16.

Sun P, Ye L, Mason M, Jiang W . Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer. J Cancer Res Clin Oncol. 2013; 139(7):1129-39. DOI: 10.1007/s00432-013-1421-5. View

17.

Agarwal S, Al-Keilani M, Alqudah M, Sibenaller Z, Ryken T, Assem M . Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma. PLoS One. 2013; 8(5):e62852. PMC: 3656086. DOI: 10.1371/journal.pone.0062852. View

18.

Januchowski R, Wojtowicz K, Zabel M . The role of aldehyde dehydrogenase (ALDH) in cancer drug resistance. Biomed Pharmacother. 2013; 67(7):669-80. DOI: 10.1016/j.biopha.2013.04.005. View

19.

Stevenson W, Best O, Przybylla A, Chen Q, Singh N, Koleth M . DNA methylation of membrane-bound tyrosine phosphatase genes in acute lymphoblastic leukaemia. Leukemia. 2013; 28(4):787-93. DOI: 10.1038/leu.2013.270. View

20.

Januchowski R, Wojtowicz K, Andrzejewska M, Zabel M . Expression of MDR1 and MDR3 gene products in paclitaxel-, doxorubicin- and vincristine-resistant cell lines. Biomed Pharmacother. 2013; 68(1):111-7. DOI: 10.1016/j.biopha.2013.09.004. View